Some information on how to participate with NephJC at PBFluids.com.
eAJKD published a short post on NephJC by Joel.
The Renal Fellow Network posted a nice introduction to the journal club by Paul Phellan.
This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterogeneity, and methodological trade-offs that frame this as direction-finding rather than definitive evidence.
This week, we will discuss why a large registry cohort was needed to move past decades of scattered case reports and clarify the true risk of hydralazine‑associated vasculitis. When rare events hide in noise, only scale can reveal the signal. Can population‑level data finally bring this paradox into focus?
Summary of the STEPS trial which will be a twitter spaces discussion
This week, we will discuss the HIT trial- a large randomized study challenging one of the most reflexive responses in hospital medicine: see hyponatremia, fix the sodium. But what if correcting the number doesn’t change what actually matters?
Some information on how to participate with NephJC at PBFluids.com.
eAJKD published a short post on NephJC by Joel.
The Renal Fellow Network posted a nice introduction to the journal club by Paul Phellan.
Can we keep the momentum for #NephJC going after the first two Journal Clubs?
@kidney_boy Main problem: how to get a large enough audience on a topic like neprhology.The 1st 2 times may not be a problem, but then?
— Laika (Jacqueline) (@laikas) April 28, 2014
We posted at Medium before we had NephJC.com up and running. You can find these posts here:
The whats, whys and whens explained
Educational programs improve survival of patients with CKD
We are using 99Design to find a logo for NephJC.
Any one of these could become the logo for #NephJC. Exciting! pic.twitter.com/0icEHEMeID
— Joel Topf (@kidney_boy) April 26, 2014